News
We recently published a list of the 10 Best High Short Interest Stocks to Buy Now. In this article, we are going to take a ...
The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) ...
H.C. Wainwright reiterates Cytokinetics (CYTK) as a top pick after Bristol-Myers (BMY) announced that the Phase 3 ODYSSEY-HCM clinical trial ...
Cytokinetics (CYTK) stock rises and rival Edgewise (EWTX) stock drops as the latter posts mixed Phase 2 trial data for its heart disorder therapy EDG-7500. Read more here.
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to ...
California Public Employees Retirement System trimmed its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – ...
Franklin Resources Inc. boosted its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 1.7% in the fourth quarter, HoldingsChannel reports. The firm owned 545,813 shares of ...
J&J also raised its full-year revenue guidance to include sales of the psychiatric drug Caplyta, which the company got from ...
Cytokinetics (CYTK) shares rallied 5.4% in the last trading session to close at $45.43. This move can be attributable to notable volume with a higher number of shares being traded than in a ...
Aficamten, a cardiac myosin inhibitor (CMI), is the cornerstone of Cytokinetics' near-term prospects. The drug has shown promising results in clinical trials, demonstrating significant gradient ...
SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company’s management team are scheduled to ...
Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results